What kind of drug does dacomitinib/dacomitinib (Dozerun) belong to and its main indications?

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation EGFR targeted inhibitor and is a highly discussed class of drugs in the global lung cancer treatment field in recent years. Unlike early EGFR drugs, dacomitinib binds more firmly to the receptor and has a wider range of inhibition, giving it deeper action properties in controlling tumor growth signals and delaying disease progression. It blocks key signaling pathways on which tumor cell proliferation depends, causing cancer cells to gradually lose their ability to expand in the absence of growth instructions. Therefore, it is considered a more comprehensive EGFR inhibition program in clinical practice.

The main indications of dacomitinib are concentrated in patients with EGFR sensitive mutations non-small cell lung cancer , especially for those in the initial treatment stage or those who need stable long-term control. For this group of people, the EGFR pathway is often the core driving force for tumor occurrence and continued growth, and the mechanism of action of dacomitinib is precisely the key point of precise inhibition, so it has been listed as one of the first-line options in the guidelines. Many patients have gradually improved their symptoms such as cough, shortness of breath, and physical decline after taking the drug. Imaging examinations may also show tumor control trends. This phenomenon is relatively common in real-world use around the world.

It is worth emphasizing that dacomitinib is not suitable for all lung cancer patients, but for people with specific mutation types. Therefore, genetic testing is usually required before use to ensure that the target is clear and the medication is matched. With the popularization of the concept of precision medicine in recent years, more and more doctors tend to customize treatment plans based on patients' genetic characteristics. It is against this background that dacomitinib has gained attention.

Overall, dacomitinib is a highly selective targeted drug with EGFR as its core target. It has a clear range of indications and a clear treatment concept. It is an important part of the era of precision treatment of non-small cell lung cancer. For mutation-positive patients, it provides a relatively controllable, long-term treatment option.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro